Castle biosciences to present new data at 2024 asco® annual meeting highlighting use of decisiondx®-melanoma to identify early-stage melanoma patients at high risk of metastasis to the central nervous system to prompt use of imaging surveillance

Friendswood, texas--(business wire)---- $cstl #asco--castle will present new data related to its decisiondx-melanoma and decisiondx-um tests at the 2024 asco annual meeting, may 31-june 4, 2024.

CSTL Ratings Summary

CSTL Quant Ranking